Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study

The International Journal of Neuroscience
Hubert H FernandezStephan Eisenschenk

Abstract

Polysomnographic studies of Parkinson's disease (PD) patients with visual hallucinations (VH) usually reveal short, fragmented rapid eye movement (REM) sleep, with lower sleep efficiency and reduced total REM sleep. Quetiapine has been demonstrated in open-label trials to be effective for the treatment of insomnia and VH in PD. To confirm quetiapine's efficacy in improving VH, and to determine whether the mechanism was due to its effect on REM sleep architecture, we performed a pilot, double-blind, placebo-controlled study. Sixteen PD patients experiencing VH were recruited. Eight patients were randomized to quetiapine and eight patients to placebo. Patients underwent pre- and post-treatment polysomnography. The Clinical Global Impression Scale (CGIS), Brief Psychiatric Rating Scale (BPRS), and Unified Parkinson Disease Rating Scale (UPDRS) motor subscale were obtained. There were no differences in baseline characteristics between the treatment arms except that the placebo group had more sleep in stage REM (74.7 min vs. 40.1 min; p < .001). Data were imputed for all patients who prematurely discontinued (four quetiapine and one placebo) in an intention-to-treat analysis. The average quetiapine dose was 58.3 mg/day. While there ...Continue Reading

References

Jan 26, 1999·Movement Disorders : Official Journal of the Movement Disorder Society·E J PappertS Leurgans
Mar 11, 1999·The New England Journal of Medicine·UNKNOWN Parkinson Study Group
Apr 10, 2002·Neurology·I ArnulfY Agid
Sep 17, 2002·Journal of Geriatric Psychiatry and Neurology·Joseph H Friedman, Hubert H Fernandez
May 2, 2003·Movement Disorders : Official Journal of the Movement Disorder Society·Hubert H FernandezJoseph H Friedman
Jun 20, 2003·Movement Disorders : Official Journal of the Movement Disorder Society·Takashi NomuraKenji Nakashima
Apr 1, 2005·Movement Disorders : Official Journal of the Movement Disorder Society·William G OndoGeorge Ringholz
Aug 3, 2005·Clinical Neuropharmacology·Carlos JuriTeresa Parrao
Oct 13, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·Jose M RabeyColin Klein
Jan 5, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·Hubert H FernandezChristopher G Goetz
Jul 31, 2008·Drugs & Aging·Laura B Zahodne, Hubert H Fernandez

❮ Previous
Next ❯

Citations

Sep 16, 2010·Current Treatment Options in Neurology·Laura B Zahodne, Hubert H Fernandez
Mar 15, 2013·Neuropsychiatric Disease and Treatment·David J Pedrosa, Lars Timmermann
Jan 28, 2014·Current Treatment Options in Neurology·Jennifer G Goldman, Samantha Holden
Nov 30, 2013·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Barbara Connolly, Susan H Fox
Jun 17, 2014·Current Treatment Options in Neurology·Scott J KutscherDaniel O Claassen
Aug 21, 2015·Expert Review of Neurotherapeutics·Umer Akbar, Joseph H Friedman
Sep 1, 2011·Progress in Neurobiology·Philippe HuotJonathan M Brotchie
Dec 17, 2010·Parkinsonism & Related Disorders·Michael J AminoffUNKNOWN National Parkinson Foundation Working Group on Hospitalization in Parkinson's Disease
Nov 2, 2011·Movement Disorders : Official Journal of the Movement Disorder Society·Klaus SeppiCristina Sampaio
Apr 24, 2014·Movement Disorders : Official Journal of the Movement Disorder Society·Murat EmreErgun Y Uç
Apr 7, 2016·Current Neurology and Neuroscience Reports·Jeffrey W Cooney, Mark Stacy
Jul 24, 2015·BJPsych Open·Ketan Dipak Jethwa, Oluwademilade A Onalaja
Sep 11, 2013·Expert Opinion on Pharmacotherapy·Joseph H Friedman
May 23, 2014·Expert Opinion on Pharmacotherapy·Leora L Borek, Joseph H Friedman
Jun 4, 2011·Expert Opinion on Pharmacotherapy·Jennifer G GoldmanChristopher G Goetz
May 17, 2011·Journal of the Neurological Sciences·George ZhongSimon John Geoffrey Lewis
Jul 14, 2016·Neurodegenerative Disease Management·Daniel Martinez-RamirezMichael S Jaffee
Sep 16, 2016·Current Psychiatry Reports·Oluwadamilola O Ojo, Hubert H Fernandez
Sep 10, 2016·Expert Opinion on Pharmacotherapy·Ines Chendo, Joaquim J Ferreira
Apr 8, 2017·The Annals of Pharmacotherapy·Kyle John WilbyMary H H Ensom
Apr 9, 2016·Journal of Geriatric Psychiatry and Neurology·Philippe DesmaraisPaulina Bajsarowicz
Nov 19, 2011·Journal of Pharmacy Practice·Joseph H Friedman
Dec 24, 2010·Therapeutic Advances in Neurological Disorders·Paul ShotboltAnthony David
Sep 18, 2015·Journal of Geriatric Psychiatry and Neurology·Massimiliano BuoliAlfredo Carlo Altamura
Aug 10, 2016·Journal of Geriatric Psychiatry and Neurology·Sara Garcia-Ptacek, Milica G Kramberger
Nov 2, 2016·Therapeutic Advances in Neurological Disorders·Harini Sarva, Claire Henchcliffe
Nov 22, 2017·Neurodegenerative Disease Management·Ruth B SchneiderIrene H Richard
Jun 22, 2017·Praxis·Katrin Rauen, Steffi Weidt
Jan 28, 2018·Current Psychiatry Reports·Shyam C Panchal, William G Ondo
Mar 20, 2013·Journal of Psychiatric Practice·Rosa Quelhas
Jun 5, 2019·Expert Review of Clinical Pharmacology·Kelly E LyonsStuart Isaacson
Jan 27, 2012·Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række·Arvid RongveDag Arsland
Mar 9, 2019·The Journal of Neuropsychiatry and Clinical Neurosciences·Jack J ChenKhashayar Dashtipour
Sep 6, 2019·Journal of Medical Genetics·Lei MouPedro Fernandez-Funez
May 15, 2015·Clinical Neuropharmacology·Unax LertxundiJuan Carlos García-Moncó
Mar 28, 2020·Journal of Neurology, Neurosurgery, and Psychiatry·John O'BrienDominic Ffytche
Jun 2, 2017·Current Treatment Options in Neurology·Amy W AmaraAleksandar Videnovic
Jan 26, 2021·Parkinson's Disease·Khashayar DashtipourJohn C Morgan
Jun 2, 2020·Parkinsonism & Related Disorders·Kevin Kyle, Jeff M Bronstein

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Movement Disorders : Official Journal of the Movement Disorder Society
Hubert H FernandezJoseph H Friedman
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
L MorganteAldo Quattrone
Movement Disorders : Official Journal of the Movement Disorder Society
Jose M RabeyColin Klein
© 2022 Meta ULC. All rights reserved